Form 4: Boston Scientific Executive Arthur C. Butcher Reports Stock Transactions

Arthur C. Butcher, an Executive Vice President at Boston Scientific, reported the acquisition and disposal of company stock and derivative securities on August 26, 2024, according to a pre-established Rule 10b5-1 trading plan.

Summary

• On August 26, 2024, Arthur C. Butcher, an EVP at Boston Scientific, reported transactions involving the company's stock.
• Butcher acquired 3,176 shares of common stock at $22.71 and 1,009 shares at $17.26 through option exercises.
• He also disposed of 14,012 shares at a weighted average price of $79.2546.
• Following these transactions, Butcher directly owns 10,802 shares and indirectly owns 13,381 shares through a 401(k) plan.
• Butcher also owns options to purchase 5,045 shares at $17.26 and 15,883 shares at $22.71.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock transactions by an executive under a pre-established plan. There is no indication of unusual or concerning activity.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a planned and potentially less reactive approach to stock transactions.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the trading activities of insiders.

Comparison to Industry Standards

• Executive stock transactions are a normal part of compensation and wealth management in publicly traded companies like Boston Scientific.
• Similar filings are regularly made by executives at comparable companies such as Medtronic (MDT) and Abbott Laboratories (ABT).
• The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading, aligning with industry best practices.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates